Mealey's (September 11, 2018, 2:23 PM EDT) -- WASHINGTON, D.C. — In a divided Sept. 10 holding, the Federal Circuit U.S. Court of Appeals upheld findings by a Delaware federal judge that four Acorda Therapeutics Inc. patents relating to the multiple sclerosis drug “Ampyra” are obvious (Acorda Therapeutics Inc. v. Roxane Laboratories Inc., et al., No. 17-2078, Fed. Cir., 2018 U.S. App. LEXIS 25536)....